Shalini S. Yadav
Growing clinical evidence suggests that a majority of cancer patients present with “intratumoral heterogeneity”—that is, not only do tumors at one site in their body differ from those at another,...Read More
Steven Frank
Dr. Frank earned his certification in Nuclear Engineering from the United States Naval Nuclear Propulsion Program and an MD degree from Emory University. He completed a Fellowship in Radiation Oncology...Read More
Eliezer Van Allen, MD
Dr. Eliezer Van Allen is an Assistant Professor of Medicine at Harvard Medical School, the Computational Director for the Center for Cancer Precision Medicine at Dana-Farber Cancer Institute, and Associate...Read More
Daniel Thorek
Treatment of advanced, metastatic prostate cancer, although greatly improved with new treatments, still represents an unmet medical need. Prostate cancer expresses a molecule called hK2 (human Kallikrein 2), an enzyme...Read More
Adam Feldman
Dr. Feldman earned a BA degree in the Biological Basis of Behavior from the University of Pennsylvania, an MA degree from Boston University School of Medicine, an MD degree from...Read More
Nicole Simone
IGF (Insulin-like Growth Factor) receptor is dysregulated during prostate cancer progression. Dr. Simone and colleagues have demonstrated that caloric restriction decreases tumor growth and metastases in animal models of prostate...Read More
Matthew Schiewer
Deficiencies in the repair of DNA are a hallmark of cancer. A molecule, named PARP, is involved in DNA damage repair. The inhibition of PARP with specific medications is a...Read More
Eleni Efstathiou
Dr. Efsathiou earned both MD and PhD degrees at the University of Athens and is currently a medical oncology fellow at MD Anderson Cancer Center. New experimental medications that shut...Read More
Jennifer Rider
Low vitamin D levels in blood have been shown in numerous population-based studies to correlate with prostate cancer mortality. Also, several genetic alterations in the vitamin-D pathway-related genes have been...Read More
